HCHF
13.5.2020 23:03:10 CEST | Business Wire | Press release
In response to the Higher Committee of Human Fraternity (HCHF) calls to pray for humanity today, 14th May, people of all races, colours, ethnicities, and nationalities stood together in an unprecedented event to pray and supplicate to God for an end to the COVID-19 pandemic, and to guide and inspire scientists find a vaccine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005852/en/
From the very first moment the HCHF announced its great initiative, the call gained the blessing and support of the two most prominent religious leaders in the world; His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Pope of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all the world.
Judge AbdelSalam, Secretary-General of the HCHF, held an online press conference on Monday, attended by Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis, and Irina Bokova, Former Director General of UNESCO during which he announced the details of the initiative in the presence of local and international media outlets.
Judge Mohamed AbdelSalam stated: “This support for the initiative is clear evidence that we can, especially when addressing common challenges, put aside our disagreements under the banner of our human fraternity. Believing that our common human values is the driving force for the HCHF’s members to announce the call to pray, fast and perform charitable work to rid mankind of this pandemic and its consequences.”
Judge AbdelSalam also announced the launch of the official website of the ‘Pray for Humanity’ initiative (pray.forhumanfraternity.org), which will provide live coverage of the day and will serve as a digital archive for this historic day and future events of the HCHF.
The HCHF was established to implement the humanitarian principles advocated by the Document on Human Fraternity and engage all religious and international organisations in this process to achieve peace, coexistence, global citizenship and human fraternity.
The HCHF consists of a group of influential figures of diverse religious and cultural backgrounds and experts in the fields of Inter-culture communication, interfaith dialogue and social coexistence:
- Cardinal Miguel Ángel Ayuso Guixot, President of the Pontifical Council for Interreligious Dialogue of the Holy See,
- Professor Mohamed Hussein Mahrasawi, President of Al-Azhar University,
- Judge Mohamed Mahmoud AbdelSalam, Former Advisor to the Grand Imam of Al-Azhar and the Secretary-General of the Committee,
- Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation,
- Irina Bokova, Former Director General of UNESCO,
- H.E. Mohamed Khalifa Al Mubarak, Chairman of the Department of Culture in Abu Dhabi,
- Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis,
- Dr. Sultan Al Remeithi, Secretary-General of the Muslim Council of Elders,
- Leymah Gbowee, a Liberian peace activist and Nobel Peace Laureate,
- Yasser Hareb, Emirati Writer and TV Presenter
- Father Professor Dr. Ioan Sauca, the Secretary-General of the World Council of Churches.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005852/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
